Tuesday’s big stock stories: What’s likely to move the market in the next trading session

Tuesday’s big stock stories: What’s likely to move the market in the next trading session


Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., June 14, 2024. REUTERS/Brendan McDermid

Brendan Mcdermid | Reuters

Stocks @ Night is a daily newsletter delivered after hours, giving you a first look at tomorrow and last look at today. Sign up for free to receive it directly in your inbox.

Here’s what CNBC TV’s producers were watching during the rebound and what’s on the radar for the next session.

Inflation in the USA

  • Two days of key data kick-off Tuesday at 8:30 a.m. ET with the producer price index, which looks at inflation from the wholesaler’s side of the equation. Economists predict the number was up 0.2% in July from the prior month.
  • Wednesday we will get CPI, the consumer price index, also at 8:30 a.m. ET.
  • The S&P 500 is down more than 5% from its high on July 16.
  • The Nasdaq 100 is off about 10% from the July 10 high.
  • The Dow Jones Industrial Average has fallen about 5% from its July 18 high.

Gold

Home Depot

  • The home improvement (and more) giant reports quarterly numbers before the bell.
  • The stock is flat since last reporting three months ago.
  • Home Depot is 13% from the stock’s March high.
Stock Chart IconStock chart icon

hide content

Home Depot stock year to date.

Boeing

  • The airline maker reports July orders and deliveries tomorrow morning.
  • The stock is down about 10% since the last report a month ago.
  • Boeing is down 38.6% from its 52-week high in December.

Nvidia’s rebound

  • Seema Mody will report on Nvidia’s recent move.
  • The stock was up 4.1% today and it’s up 8.5% in five sessions.
  • Nvidia remains 22.5% from the 52-week high it hit on June 20.
Stock Chart IconStock chart icon

hide content

Nvidia shares over the past three months.

The other six of the ‘Magnificent Seven’

  • Meta is 5% from its July 8 high.
  • Apple is 8.3% from its July 15 high.
  • Microsoft is 13% from its July 5 high.
  • Alphabet is 15.3% from its July 10 high.
  • Amazon is 17% from its July 8 high.
  • Tesla is 29% from its Sept. 15 high.

Tesla vs. China

  • CNBC’s Eunice Yoon, who reports from China, will look at Tesla’s Chinese competitors tomorrow.
  • All the big ones are down in August, over the last month and three months.
  • Li Auto is down 27% in three months; the stock is 58% from its Feb. 27 high.
  • Xpeng is down 25% in one month, and is 67% from its Sept. 1 high.
  • BYD is down 13% in a month, 17% below its 52-week high.
  • Zeekr is down 26% in a month, and has fallen 55% since its May 13 high.
  • Nio is down 26% in three months, and has tumbled 71% since its 52-week high nearly a year ago.

13F filings

  • CNBC will be checking on the stocks the biggest fundrunners in the country are buying and selling. The 13F filings to the Securities and Exchange Commission, which make these disclosures, start tomorrow.
  • One filing that many pay attention to is Warren Buffett’s Berkshire Hathaway.
  • BRK.A is up 19% so far in 2024 and up 4% in three months.
Stock Chart IconStock chart icon

hide content

Berkshire Hathaway shares over the past three months



Source

Economist Nouriel Roubini: Trump is likely to escalate the Iran war — risking ‘1970s stagflation’
World

Economist Nouriel Roubini: Trump is likely to escalate the Iran war — risking ‘1970s stagflation’

U.S. President Donald Trump is likely to escalate the war with Iran, risking “1970s stagflation” if it does not go as planned, renowned economist and investor Nouriel Roubini told CNBC. Speaking to CNBC’s Carolin Roth at the Ambrosetti Forum in Cernobbio, Italy on Friday, Roubini — best known for predicting the 2008 Global Financial Crisis […]

Read More
AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed
World

AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed

AstraZeneca‘s stock jumped nearly 5% after Britain’s most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials. The respiratory treatment tozorakimab, reduced flare-ups of chronic obstructive pulmonary disease (COPD) in both former smokers and in the overall population versus placebo, the company said. “This marks a notable shift […]

Read More
The Tech Download: How Russia could profit from Iran war helium supply chain disruption in the chip sector
World

The Tech Download: How Russia could profit from Iran war helium supply chain disruption in the chip sector

This report is from this week’s The Tech Download newsletter. Like what you see? You can subscribe here. Helium has emerged as a key focus for the tech sector as industry watchers cast their minds to the implications of a prolonged Iran war. A byproduct of natural gas production, helium is crucial to semiconductor manufacturing and […]

Read More